Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Ahmedabad: Intas Pharma has announced the appointment of Sarang Pande as Vice President - Digital Manufacturing & Industry ...

to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million.

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...

Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals. Intas buys Teva's UK ...

Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Intas Pharma becomes most valuable privately held pharma company A PE deal values Intas at Rs 23,000 crore or USD 3.5 billion, making it the most valued pharma privately held company in India.